Lynparza is one of the PARP (poly ADP-ribose polymerase) inhibitors. PARP inhibitors have been approved to treat ovarian cancers and prostate cancers with germline or somatic BRCA1 or BRACA2 mutations (Lin KY, et al., Cell 2017;169:183). The indications are expanded to include breast cancers on January 12th, 2018.
The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, …